Tnp 351

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H597228

CAS#: 125991-51-7

Description: Tnp 351 is a novel antifolate being evaluated for chemotherapy of lung cancer.

Chemical Structure

img
Tnp 351
CAS# 125991-51-7
Instruction

Theoretical Analysis

Hodoodo Cat#: H597228
Name: Tnp 351
CAS#: 125991-51-7
Chemical Formula: C21H24N6O5
Exact Mass: 440.18
Molecular Weight: 440.460
Elemental Analysis: C, 57.27; H, 5.49; N, 19.08; O, 18.16

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Tnp 351; Tnp-351; Tnp351;

IUPAC/Chemical Name: (4-(3-(2,4-diamino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)benzoyl)-L-glutamic acid

InChi Key: WLGCEMWNUHSIIS-AWEZNQCLSA-N

InChi Code: InChI=1S/C21H24N6O5/c22-17-16-13(10-24-18(16)27-21(23)26-17)3-1-2-11-4-6-12(7-5-11)19(30)25-14(20(31)32)8-9-15(28)29/h4-7,10,14H,1-3,8-9H2,(H,25,30)(H,28,29)(H,31,32)(H5,22,23,24,26,27)/t14-/m0/s1

SMILES Code: O=C(O)CC[C@@H](C(O)=O)NC(C1=CC=C(CCCC2=CN=C3NC(N)=NC(N)=C32)C=C1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 440.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Taylor EC, Liu B. A new and efficient synthesis of pyrrolo[2,3-d]pyrimidine anticancer agents: Alimta (LY231514, MTA), homo-Alimta, TNP-351, and some aryl 5-substituted pyrrolo[2,3-d]pyrimidines. J Org Chem. 2003 Dec 26;68(26):9938-47. PubMed PMID: 14682686.

2: Itoh F, Yoshioka Y, Yukishige K, Yoshida S, Ootsu K, Akimoto H. Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. III. Synthesis and biological properties of N(omega)-masked ornithine analogs. Chem Pharm Bull (Tokyo). 2000 Sep;48(9):1270-80. PubMed PMID: 10993224.

3: Matsuo K, Kiura K, Ueoka H, Tabata M, Shibayama T, Matsumura T, Takigawa N, Hiraki S, Harada M. Growth inhibitory effects of antifolates against an adriamycin-resistant human small cell lung cancer cell line. Acta Med Okayama. 1997 Jun;51(3):121-7. Erratum in: Acta Med Okayama 1997 Aug;51(4):237. PubMed PMID: 9227790.

4: Taylor EC, Mao Z. A Ring-Transformation/Ring-Annulation Strategy for the Synthesis of the DHFR Inhibitor, TNP-351: A Correction. J Org Chem. 1996 Nov 1;61(22):7973-7974. PubMed PMID: 11667765.

5: Itoh F, Yoshioka Y, Yukishige K, Yoshida S, Wajima M, Ootsu K, Akimoto H. Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. II. Synthesis and antitumor activity of N5-substituted glutamine analogs. Chem Pharm Bull (Tokyo). 1996 Aug;44(8):1498-509. PubMed PMID: 8795269.

6: Taguchi T, Niitani H, Furue H, Tsukagoshi S, Kanamaru R, Hasegawa K, Akazawa S, Yoneda S, Tominaga T, Sasaki T, et al. [The clinical phase I study of TNP-351. The TNP-351 Research Committee]. Gan To Kagaku Ryoho. 1995 Feb;22(2):259-71. Japanese. PubMed PMID: 7857102.

7: Aso K, Hitaka T, Yukishige K, Ootsu K, Akimoto H. Synthesis and antitumor activity of pyrrolo[2,3-d]pyrimidine antifolates with a bridge chain containing a nitrogen atom. Chem Pharm Bull (Tokyo). 1995 Feb;43(2):256-61. PubMed PMID: 7728932.

8: Itoh F, Yukishige K, Wajima M, Ootsu K, Akimoto H. Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. I: Synthesis and biological properties of pyrrolo[2,3-d]pyrimidine antifolates containing tetrazole congener of glutamic acid. Chem Pharm Bull (Tokyo). 1995 Feb;43(2):230-5. PubMed PMID: 7728929.

9: Itoh F, Russello O, Akimoto H, Beardsley GP. Novel pyrrolo[2,3-d]pyrimidine antifolate TNP-351: cytotoxic effect on methotrexate-resistant CCRF-CEM cells and inhibition of transformylases of de novo purine biosynthesis. Cancer Chemother Pharmacol. 1994;34(4):273-9. PubMed PMID: 8033293.

10: Tsukagoshi S. [Development of antimetabolites, II]. Gan To Kagaku Ryoho. 1993 Jan;20(1):19-26. Review. Japanese. PubMed PMID: 8422184.

11: Yoshimura A. [New analogues of methotrexate]. Gan To Kagaku Ryoho. 1992 Nov;19(13):2133-9. Review. Japanese. PubMed PMID: 1444480.